Financial Survey: bioMerieux (OTCMKTS:BMXMF) versus Embecta (NASDAQ:EMBC)

Embecta (NASDAQ:EMBC) and bioMerieux (OTCMKTS:BMXMF) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk.

Volatility & Risk

Embecta has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Comparatively, bioMerieux has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500.

Institutional and Insider Ownership

93.8% of Embecta shares are held by institutional investors. 1.3% of Embecta shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Embecta and bioMerieux’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Embecta	10.73%	-23.96%	14.12%
bioMerieux	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent recommendations for Embecta and bioMerieux, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Embecta	2	3	0	0	1.60
bioMerieux	1	5	0	0	1.83

Embecta currently has a consensus target price of $11.00, suggesting a potential upside of 198.91%. Given Embecta’s higher probable upside, equities research analysts clearly believe Embecta is more favorable than bioMerieux.

Earnings & Valuation

This table compares Embecta and bioMerieux”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Embecta	$1.08 billion	0.20	$95.40 million	$1.90	1.94
bioMerieux	$4.60 billion	2.03	$449.73 million	N/A	N/A

bioMerieux has higher revenue and earnings than Embecta.

Summary

Embecta beats bioMerieux on 6 of the 11 factors compared between the two stocks.

About Embecta

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

About bioMerieux

bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. It also provides a suite of software products and services that collect, analyze, and merge various sources of data to make decisions under the BIOMÉRIEUX VISION SUITE name; designs, manufactures, and maintains instruments and software; and designs and manufactures reagents for in vitro diagnostic tests. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.